KR970706815A - 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron) - Google Patents

온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)

Info

Publication number
KR970706815A
KR970706815A KR1019970703400A KR19970703400A KR970706815A KR 970706815 A KR970706815 A KR 970706815A KR 1019970703400 A KR1019970703400 A KR 1019970703400A KR 19970703400 A KR19970703400 A KR 19970703400A KR 970706815 A KR970706815 A KR 970706815A
Authority
KR
South Korea
Prior art keywords
composition
ondansetron
sweetener
terms
polyhydric alcohol
Prior art date
Application number
KR1019970703400A
Other languages
English (en)
Other versions
KR100292124B1 (ko
Inventor
레누 갬버
Original Assignee
그레이햄 브레레턴
글락소 웰컴 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR970706815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 그레이햄 브레레턴, 글락소 웰컴 인크. filed Critical 그레이햄 브레레턴
Publication of KR970706815A publication Critical patent/KR970706815A/ko
Application granted granted Critical
Publication of KR100292124B1 publication Critical patent/KR100292124B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 온단세트론 또는 약학적으로 허용가능한 그의 유도체, 감미료 및 하나 이상의 약학적으로 허용가능한 부형제를 포함하며 감미료가 하나 이상의 다가 알코올을 포함하고, 조성물의 pH가 2.0 내지 5.0범위인 경구 투여용 액체 조성물에 관한 것이다. 또한 그러한 조성물의 제조 방법, 및 5HT3수용체에서 5-히드록시트 립타민(5HT)의 작용을 통해 매개되는 증상의 치료에서의 사용 방법을 설명한다.

Description

온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 온단세트론 또는 제약학적으로 허용가능한 그의 유도체, 감미료 및 하나 이상의 제약학적으로 허용가능한 부형제를 포함하며 감미료가 하나 이상의 다가 알코올을 포함하고, 조성물의 pH가 2.0 내지 5.0범위인 경구투여용 액체 조성물.
  2. 제1항에 있어서, 염산염 형태의 온단세트론을 포함하는 조성물.
  3. 제1항에 있어서, 염산염 이수화물 형태의 온단세트론을 포함하는 조성물.
  4. 제1항 내지 3항 중 어느 한 항에 있어서, 감미료가 소로비톨을 포함하는 조성물.
  5. 제4항에 있어서, 염산염 이수화물 형태의 온단세트론과 감미료로서 소로비톨을 포함하는 조성물.
  6. 제1항 내지 5항 중 어느 한 항에 있어서, 조성물 중의 온단세트론의 농도가 유리 염기로 환산하여 0.005 내지 1%w/v 범위인 조성물.
  7. 제1항 내지 6항 중 어느 한 항에 있어서, 조성물 중의 다가 알코올의 총 함량이 다가 알코올 고체로 환산하여 20 내지 85%w/v 범위인 조성물.
  8. 제1항 내지 7항 중 어느 한 항에 있어서, pH가 2.5 내지 4.5범위인 조성물.
  9. 제1항에 내지 8항 중 어느 한 항에 있어서, 조성물 중의 온단세트론의 농도가 유리 염기로 환산하여 0.005 내지 1%w/v 범위이고, 조성물 중의 다가 알코올의 총함량이 다가 알코올 고체로 환산하여 20 내지 85%w/v범위이며, pH가 2.5 내지 4.5범위인 조성물.
  10. 제1항 내지 9항 중 어느 한 항에 있어서, 점도가 1 내지 100cps 범위인 조성물.
  11. 제1항 내지 10항 중 어느 한 항에 있어서, 과당 또는 과당 함유 사카라이드를 실절적으로 포함하지 않는 조성물.
  12. 제1항 내지 11항 중 어느 한 항에 따른 조성물을 투여하는 것을 포함하는, 5HT3, 수용체에서 5HT의 작용을 통해 매개되는 증상을 고통받는 포유류(사람 포함)를 치료하는 방법.
  13. 제12항에 있어서, 구토증 치료를 위한 방법
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703400A 1994-11-22 1995-11-20 온단세트론을포함하는경구조성물 KR100292124B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423588.4 1994-11-22
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions
PCT/IB1995/001152 WO1996015786A2 (en) 1994-11-22 1995-11-20 Oral compositions containing ondansetron

Publications (2)

Publication Number Publication Date
KR970706815A true KR970706815A (ko) 1997-12-01
KR100292124B1 KR100292124B1 (ko) 2001-07-12

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703400A KR100292124B1 (ko) 1994-11-22 1995-11-20 온단세트론을포함하는경구조성물

Country Status (33)

Country Link
US (1) US5854270A (ko)
EP (1) EP0792149B1 (ko)
JP (1) JP2965704B2 (ko)
KR (1) KR100292124B1 (ko)
CN (1) CN1108153C (ko)
AT (1) ATE196084T1 (ko)
AU (1) AU703932B2 (ko)
BE (1) BE1009458A5 (ko)
BR (1) BR9509807A (ko)
CA (1) CA2205546C (ko)
CY (1) CY2171B1 (ko)
CZ (1) CZ285187B6 (ko)
DE (1) DE69518767T2 (ko)
DK (1) DK0792149T3 (ko)
ES (1) ES2151083T3 (ko)
FI (1) FI119356B (ko)
FR (1) FR2727015B1 (ko)
GB (2) GB9423588D0 (ko)
GR (1) GR3034684T3 (ko)
HK (1) HK1009590A1 (ko)
HU (1) HU226947B1 (ko)
IE (1) IE950884A1 (ko)
IL (1) IL116083A (ko)
IT (1) IT1282353B1 (ko)
NO (1) NO306892B1 (ko)
NZ (1) NZ297879A (ko)
PL (1) PL181522B1 (ko)
PT (1) PT792149E (ko)
RU (1) RU2145853C1 (ko)
SI (1) SI0792149T1 (ko)
TW (1) TW413634B (ko)
WO (1) WO1996015786A2 (ko)
ZA (1) ZA959820B (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
WO2001013909A2 (en) * 1999-08-25 2001-03-01 Cooper Barrett R Compositions and methods for treating opiate intolerance
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
US7098345B2 (en) * 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
CA2483532A1 (en) * 2002-04-30 2003-11-13 Biogal Gyogyszergyar Rt. Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5-羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ,インコーポレイテッド 薬学的組成物
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
EP2478099B1 (en) * 2009-09-18 2019-06-05 Chase Pharmaceuticals Corporation Combination for treating alzheimer-type dementia
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
JP2015531346A (ja) 2012-09-05 2015-11-02 チェイス・ファーマスーティカルズ・コーポレーション 抗コリン作用性神経保護組成物及び方法
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ,インコーポレイテッド 医薬組成物
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664152A5 (fr) * 1984-01-25 1988-02-15 Glaxo Group Ltd Derives de tetrahydrocarbazolones.
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
FI972168A (fi) 1997-05-21
WO1996015786A3 (en) 1996-06-27
DK0792149T3 (da) 2000-12-18
ZA959820B (en) 1996-07-29
ITRM950763A0 (ko) 1995-11-20
CN1108153C (zh) 2003-05-14
DE69518767D1 (de) 2000-10-12
PT792149E (pt) 2001-02-28
NO306892B1 (no) 2000-01-10
GB2295317A (en) 1996-05-29
CA2205546C (en) 2000-01-25
NO972324D0 (no) 1997-05-21
IE950884A1 (en) 1996-05-29
NO972324L (no) 1997-07-21
RU2145853C1 (ru) 2000-02-27
BR9509807A (pt) 1997-10-21
GR3034684T3 (en) 2001-01-31
CY2171B1 (en) 2002-08-23
MX9703734A (es) 1997-09-30
IL116083A0 (en) 1996-01-31
DE69518767T2 (de) 2001-05-31
ATE196084T1 (de) 2000-09-15
CN1171740A (zh) 1998-01-28
EP0792149B1 (en) 2000-09-06
AU703932B2 (en) 1999-04-01
AU4313596A (en) 1996-06-17
FI972168A0 (fi) 1997-05-21
KR100292124B1 (ko) 2001-07-12
BE1009458A5 (fr) 1997-04-01
HK1009590A1 (en) 1999-06-04
CZ285187B6 (cs) 1999-06-16
FR2727015A1 (fr) 1996-05-24
WO1996015786A2 (en) 1996-05-30
CA2205546A1 (en) 1996-05-30
NZ297879A (en) 1998-12-23
HUT77944A (hu) 1998-12-28
US5854270A (en) 1998-12-29
PL320288A1 (en) 1997-09-15
TW413634B (en) 2000-12-01
JP2965704B2 (ja) 1999-10-18
FI119356B (fi) 2008-10-31
JPH10508866A (ja) 1998-09-02
HU226947B1 (en) 2010-03-29
ES2151083T3 (es) 2000-12-16
GB2295317B (en) 1998-11-25
GB9423588D0 (en) 1995-01-11
FR2727015B1 (fr) 1997-08-22
PL181522B1 (en) 2001-08-31
ITRM950763A1 (it) 1997-05-20
IT1282353B1 (it) 1998-03-20
CZ154897A3 (en) 1997-10-15
GB9523666D0 (en) 1996-01-24
SI0792149T1 (en) 2001-02-28
IL116083A (en) 2000-09-28
EP0792149A2 (en) 1997-09-03

Similar Documents

Publication Publication Date Title
KR970706815A (ko) 온단세트론을 포함하는 경구 조성물(Oral Compositions Containing Ondansetron)
KR970706814A (ko) 동결 건조된 온단세트론 조성물(Freeze-Dried Ondansetron Compositions)
RU97110066A (ru) Содержащие ондансетрон составы для перорального введения
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
RU2220723C2 (ru) Средство и способ лечения или профилактики артериосклероза
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
EE03235B1 (et) Emulsioonvorm, selle valmistamise protsess ja kasutamine
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
KR910002792A (ko) 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물
KR910014121A (ko) 위궤양 및 미란 치료용인 시메티딘-피렌제핀 제제
KR970702054A (ko) 헬리코박터 파이로리에 기인한 위장 기능장해 치료를 위한 스피라마이신의 용도(use of spiramycin for treating gastrointestinal disorders caused by h. pylori)
ES2175086T3 (es) Composiciones farmaceuticas anti-emeticas que contienen metotrimeprazina.
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
KR970073595A (ko) 알콜성 장해 예방 및 치료제 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 13

FPAY Annual fee payment

Payment date: 20140227

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20150227

Year of fee payment: 15

EXPY Expiration of term